Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 521-541 , September 2008

Dendritic cell vaccines in acute leukaemia

  • Caroline Duncan, MBBS, MRCP (Ed) (Clinical Research Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 0131 537 1182; Fax: +44 0131 537 1172.
    • ,
  • Huw Roddie, MBChB, PhD (Consultant Haematologist)

References 

  1. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. ASH Annual Meeting Abstracts. 2006;108:13
  2. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology. 2002;118:385–400
  3. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–1833
  4. Hirano N, Takahashi T, Takahashi T, et al. Expression of costimulatory molecules in human leukemias. Leukemia. 1996;10:1168–1176
  5. Buggins AGS, Lea N, Gaken J, et al. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood. 1999;94:3479–3490
  6. Zheng Z, Takahashi M, Aoki S, et al. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Journal of Experimental & Clinical Cancer Research. 1998;17:251–258
  7. Buggins AGS, Milojkovic D, Arno MJ, et al. Microenviroment Produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-κB, c-Myc, and pRb pathways. Journal of Immunology. 2001;167:6021–6030
  8. Hirst W, Buggins A, Mufti G. Central role of leukemia-derived factors in the development of leukemia-associated immune dysfunction. The Hematology Journal. 2001;2:2–17
  9. Milojkovic D, Devereux S, Westwood NB, et al. Antiapoptotic microenvironment of acute myeloid leukemia. Journal of Immunology. 2004;173:6745–6752
  10. Wang X, Zheng J, Liu J, et al. Increased population of CD4+ CD25high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. European Journal of Haematology. 2005;75:468–476
  11. Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunological Reviews. 2007;219:143–156
  12. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. The Journal of Clinical Investigation. 1999;104:173–180
  13. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nature Reviews. Immunology. 2005;5:296–306
  14. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine. 1996;2:1096–1103
  15. Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. Journal of Immunology. 1997;159:4772–4780
  16. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. The Journal of Experimental Medicine. 1994;179:1109–1118
  17. Anton D, Dabadghao S, Palucka K, et al. Generation of dendritic cells from peripheral blood adherent cells in medium with human serum. Scandinavian Journal of Immunology. 1998;47:116–121
  18. Jeras M, Bergant M, Repnik U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transplant Immunology. 2005;14:231–244
  19. Radford KJ, Turtle CJ, Kassianos AJ, et al. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. Journal of Immunotherapy. 2006;29:596–605
  20. Thomas-Kaskel AK, Portugal TG, Herchenbach D, et al. Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. Acta Haematologica. 2007;117:226–235
  21. Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Research. 2001;61:6846–6850
  22. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286–293
  23. Osman Y, Takahashi M, Zheng Z, et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. Journal of Experimental & Clinical Cancer Research. 1999;18:485–492
  24. Makita M, Azuma T, Hamaguchi H, et al. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia. 2002;16:2400–2407
  25. Van DA, Gao L, Stauss HJ, et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia. 2005;19:1863–1871
  26. Qazilbash MH, Wieder ED, Thall PF, et al. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. ASH Annual Meeting Abstracts. 2007;110:577
  27. Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. ASH Annual Meeting Abstracts. 2004;104:259
  28. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:13885–13890
  29. Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165–166
  30. Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111:1357–1365
  31. Van Driessche A, Ponsaerts P, Van Bockstaele DR, et al. Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochemica et Cytobiologica. 2005;43:213–216
  32. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450–2457
  33. Molldrem JJ, Lee PP, Wang C, et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Research. 1999;59:2675–2681
  34. Greiner J, Li L, Ringhoffer M, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood. 2005;106:938–945
  35. Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood. 2006;108:4109–4117
  36. Chan L, Hardwick NR, Guinn BA, et al. An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy. 2006;55:1017–1024
  37. Si Fujii, Fujimoto K, Shimizu K, et al. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Research. 1999;59:2150–2158
  38. Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, et al. Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia. BMC. Cancer. 2005;5:20
  39. Spisek R, Chevallier P, Morineau N, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Research. 2002;62:2861–2868
  40. Galea-Lauri J, Darling D, Mufti G, et al. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunology, Immunotherapy. 2002;51:299–310
  41. Klammer M, Waterfall M, Samuel K, et al. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. British Journal of Haematology. 2005;129:340–349
  42. Weigel BJ, Panoskaltsis-Mortari A, Diers M, et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Experimental Hematology. 2006;34:1403–1412
  43. Sheng LX, Qiu GQ, Xie XB, et al. The comparison of inducing specific CTL by two methods of leukemia cell antigen loading of DCs and fusion of DCs with leukemia cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2005;21:205–209
  44. Delluc S, Tourneur L, Fradelizi D, et al. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method. Cancer Immunology, Immunotherapy. 2007;56:1–12
  45. Decker WK, Xing D, Li S, et al. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine. 2006;24:3203–3216
  46. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89
  47. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Current Opinion in Immunology. 2001;13:114–119
  48. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. The Journal of Experimental Medicine. 2000;191:423–434
  49. Ip WK, Lau YL. Distinct maturation of, but not migration between, human monocyte-derived dendritic cells upon ingestion of apoptotic cells of early or late phases. Journal of Immunology. 2004;173:189–196
  50. Larmonier N, Merino D, Nicolas A, et al. Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis. 2006;11:1513–1524
  51. Choudhury A, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93:780–786
  52. Roddie H, Klammer M, Thomas C, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. British Journal of Haematology. 2006;133:152–157
  53. Charbonnier A, Gaugler B, Sainty D, et al. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. European Journal of Immunology. 1999;29:2567–2578
  54. Harrison BD, Adams JA, Briggs M, et al. Stimulation of autologous proliferative and cytotoxic T-cell responses by “leukemic dendritic cells” derived from blast cells in acute myeloid leukemia. Blood. 2001;97:2764–2771
  55. Cignetti A, Vallario A, Roato I, et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. Journal of Immunology. 2004;173:2855–2865
  56. Kohler T, Plettig R, Wetzstein W, et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells. 2000;18:139–147
  57. Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. International Journal of Oncology. 2006;28:855–861
  58. Houtenbos I, Westers TM, Ossenkoppele GJ, et al. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology. 2006;211:677–685
  59. Houtenbos I, Westers TM, Hess CJ, et al. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia. 2006;20:1892–1895
  60. Roddie PH, Paterson T, Turner ML. Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines. Cytokines, Cellular & Molecular Therapy. 2000;6:127–134
  61. Cheuk AT, Chan L, Czepulkowski B, et al. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunology, Immunotherapy. 2006;55:68–75
  62. Santiago-Schwartz F, Coppock DL, Hindenburg AA, et al. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood. 1994;84:3054–3062
  63. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133–1142
  64. Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia. 2002;16:84–93
  65. Maggio R, Peragine N, Calabrese E, et al. Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission. Leukemia & Lymphoma. 2007;48:302–310
  66. Pospisilova D, Borovickova J, Polouckova A, et al. Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy. 2002;51:72–78
  67. Lee JJ, Kook H, Park MS, et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. Journal of Clinical Apheresis. 2004;19:66–70
  68. Roddie H., 2008. Personal Communication. Consultant Haematologist, Dept of Haematology, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU. Fax 0131 537 1172.
  69. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia – definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica. 2006;91:1653–1661
  70. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clinical and Experimental Immunology. 2007;148:189–198
  71. Rezvani K, Yong ASM, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236–242
  72. Zhang WG, Liu SH, Cao XM, et al. A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6. Leukemia Research. 2005;29:3–9
  73. Janetzki S, Cox JH, Oden N, et al. Standardization and validation issues of the ELISPOT assay. Methods in Molecular Biology. 2005;302:51–86
  74. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunology, Immunotherapy. 2008;57:303–315
  75. Royer PJ, Bougras G, Ebstein F, et al. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy. Experimental Hematology. 2008;36:329–339
  76. Westermann J, Korner IJ, Kopp J, et al. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunology, Immunotherapy. 2003;52:194–198
  77. Tschoep K, Manning TC, Harlin H, et al. Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines. Journal of Leukocyte Biology. 2003;74:69–80
  78. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood. 2002;100:174–177
  79. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435–1440
  80. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clinical Cancer Research. 2003;9:5091–5100
  81. Fujita S, Seino Ki, Sato K, et al. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood. 2006;107:3656–3664
  82. Seliger B, Atkins D, Bock M, et al. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clinical Cancer Research. 2003;9:1721–1727
  83. Ohashi T, Hanabuchi S, Suzuki R, et al. Correlation of major histocompatibility complex class I downregulation with resistance of human T-cell leukemia virus type 1-infected T cells to cytotoxic T-lymphocyte killing in a rat model. Journal of Virology. 2002;76:7010–7019
  84. Kebelmann-Betzing C, Korner G, Badiali L, et al. Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all. Cytokine. 2001;13:39–50
  85. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061
  86. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804–811
  87. Liu JY, Wu Y, Zhang XS, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunology, Immunotherapy. 2007;56:1597–1604
  88. Lutsiak MEC, Semnani RT, De Pascalis R, et al. Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868
  89. Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clinical and Experimental Immunology. 2007;150:523–530
  90. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655–2661
  91. Mizukami Y, Kono K, Kawaguchi Y, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3(+) regulatory T cells in gastric cancer. International Journal of Cancer. 2008;122(10):2286–2293
  92. Kosmidis S, Baka M, Bouhoutsou D, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatric Blood & Cancer. 2008;50:528–532
  93. Bruserud O, Ulvestad E, Berentsen S, et al. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation. Scandinavian Journal of Immunology. 1998;47:54–62
  94. Wendelbo O, Nesthus I, Sjo M, et al. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunology, Immunotherapy. 2004;53:740–747
  95. Snyder JT, exander-Miller MA, Berzofskyl JA, et al. Molecular mechanisms and biological significance of CTL avidity. Current HIV research. 2003;1:287–294
  96. Niiya T, Akbar S, Yoshida O, et al. Impaired dendritic cell function resulting from chronic undernutrition disrupts the antigen-specific immune response in mice. The Journal of Nutrition. 2007;137:671–675
  97. Dalgaard J, Beckstrom KJ, Brinchmann JE. Uptake of apoptotic K562 leukaemia cells by immature dendritic cells is greatly facilitated by serum. Scandinavian Journal of Immunology. 2003;58:541–549
  98. Martin-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. The Journal of Experimental Medicine. 2003;198:615–621
  99. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. European Urology. 2006;50:34–43
  100. Houtenbos I, Westers TM, Dijkhuis A, et al. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clinical Cancer Research. 2007;13:307–315
  101. Luczynski W, Kowalczuk O, Ilendo E, et al. Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Annals of Hematology. 2007;86:339–345
  102. Terheyden P, Straten Pt, Brocker EB, et al. CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-γ-producing T cells from tumor-infiltrating lymphocytes. Journal of Immunology. 2000;164:6633–6639
  103. Ramakrishna V, Vasilakos JP, Tario JD, et al. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. Journal of Translational Medicine. 2007;5:5
  104. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. The Journal of Clinical Investigation. 2005;115:739–746
  105. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614–2627
  106. Matsumoto A, Haraguchi K, Takahashi T, et al. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. International Journal of Urology. 2007;14:277–283
  107. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103:1787–1790
  108. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618–621
  109. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. The Journal of Clinical Investigation. 2005;115:3623–3633
  110. Nair S, Boczkowski D, Fassnacht M, et al. Vaccination against the Forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Research. 2007;67:371–380
  111. Figdor CG, de Vries I, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nature Medicine. 2004;10:475–480

PII: S1521-6926(08)00066-2

doi: 10.1016/j.beha.2008.07.010

Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 521-541 , September 2008

Article Tools

* Image Usage & Resolution